A total of 33 patients received tumor cell genetic testing; 19 had an EGFR mutation (19del, 20ins 21L858R), 9 had the ALK fusion gene, 9 had a ROS1 gene mutation, and 3 had a HER2 mutation. The gene discussed is ERBB2; the disease is neoplasm.